Group |
Total |
P-value |
Between 2nd
and 3rd doses |
P-value |
After 3rd dose |
P-value |
Controls |
80 |
|
80 |
|
30 |
|
|
28 (35%) |
|
13 (16.3%) |
|
15 (50%) |
|
AIIRD patients |
124 |
|
124 |
|
64 |
|
|
59 (47.6) |
0.1033 |
33 (26.6%) |
0.1193 |
26 (40.6%) |
0.5278 |
JIA |
54 |
|
54 |
|
23 |
|
|
26 (48.2) |
0.1794 |
17 (31.5%) |
0.0624 |
9 (39.1%) |
0.6104 |
SLE |
20 |
|
20 |
|
10 |
|
|
7 (35%) |
1 |
3 (15%) |
1 |
4 (40%) |
0.855 |